In a Phase Ib clinical trial involving patients with metastatic HER‐2‐negative breast cancer, riparexin—an allosteric CXCR1/2 inhibitor—demonstrated promising activity against breast cancer stem cells when used in combination with paclitaxel [80]. Here, ERBB2 is linked to breast carcinoma.